Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB)
3.1900
-0.0500 (-1.54%)
NASDAQ · Last Trade: Jul 25th, 9:52 PM EDT
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via Chartmill · July 24, 2025
Via Benzinga · July 23, 2025
Via Benzinga · July 23, 2025

H.C.
Via Benzinga · September 18, 2023
Via Benzinga · July 23, 2025
Via Benzinga · March 27, 2025
Via Benzinga · March 13, 2025

Via Benzinga · December 26, 2024

Via Benzinga · December 24, 2024

ANEB stock results show that Anebulo Pharmaceuticals beat analyst estimates for earnings per share the third quarter of 2024.
Via InvestorPlace · May 15, 2024

Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday second quarter financial results for the three months ended Dec. 31, 2023, The company's primary focus is on developing therapy for acute cannabinoid intoxication (ACI).Total operating expenses in the second quarter of fiscal 2024 were $2.8 million compared with $3.8 million in the same period in fiscal 2023.Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.
Via Benzinga · February 14, 2024

Via Benzinga · December 21, 2023

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
Via Benzinga · October 17, 2023

Via Benzinga · October 17, 2023

Via Benzinga · September 18, 2023

Via Benzinga · August 22, 2023

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced positive feedback from the United States Food and Drug Administration following a type B meeting in July.
Via Benzinga · August 21, 2023

Via Benzinga · August 21, 2023

Anebulo Pharmaceuticals, Inc.
Via Benzinga · March 29, 2023

As the Benzinga Cannabis Capital Conference returns to Miami (April 11-12), gathering top CEOs, investors and leaders in the mari
Via Benzinga · March 13, 2023

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the European market.
Via Benzinga · March 7, 2023